Briquilimab (JSP-191) is a humanized monoclonal antibody engineered to target CD117 (c-Kit), facilitating the depletion of hematopoietic stem cells (HSCs). This antibody is characterized by its non-toxic profile, making it an ideal agent for clearing host marrow niche spaces. The primary application of Briquilimab is to enhance donor HSC engraftment and promote immune reconstitution, particularly in the treatment of severe combined immunodeficiency (SCID). This mechanism not only supports effective hematopoietic transplantation but also ensures safety and efficacy in clinical settings.
Briquilimab (JSP-191) is a humanized monoclonal antibody engineered to target CD117 (c-Kit), facilitating the depletion of hematopoietic stem cells (HSCs). This antibody is characterized by its non-toxic profile, making it an ideal agent for clearing host marrow niche spaces. The primary application of Briquilimab is to enhance donor HSC engraftment and promote immune reconstitution, particularly in the treatment of severe combined immunodeficiency (SCID). This mechanism not only supports effective hematopoietic transplantation but also ensures safety and efficacy in clinical settings.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
